Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,674 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07346105 | Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies | available | — | — | Orca Biosystems, Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03145545 | Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC | available | — | — | Children's Hospital of PhiladelphiaOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04809233 | Expanded Access to Tipifarnib(Kuraoncology) | available | — | — | Kura Oncology, Inc.INDUSTRY | 0 | Jun 29, 2026 | clinicaltrials |
| NCT05738538 | Expanded Access to Ziftomenib | available | — | — | Kura Oncology, Inc.INDUSTRY | 0 | Jun 29, 2026 | clinicaltrials |
| NCT05776160 | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel | available | — | — | Kite, A Gilead CompanyINDUSTRY | 2 | Jun 12, 2026 | clinicaltrials |
| NCT05028166 | Individual Patient Compassionate Use of Mirdametinib | available | — | — | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 0 | May 8, 2026 | clinicaltrials |
| NCT05593185 | Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS | available | — | — | Sellas Life Sciences GroupINDUSTRY | 0 | Apr 24, 2026 | clinicaltrials |
| NCT03601442 | Managed Access Programs for CTL019, Tisagenlecleucel | available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 23, 2026 | clinicaltrials |
| NCT05776134 | Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel | available | — | — | Kite, A Gilead CompanyINDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor(KEAP) | available | — | — | Karyopharm Therapeutics IncINDUSTRY | 0 | Mar 2, 2026 | clinicaltrials |
| NCT06799221 | Expanded Access Program for OOS Obe-cel | available | — | — | Autolus LimitedINDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05346835 | Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma | available | — | — | Janssen Scientific Affairs, LLCINDUSTRY | 2 | Feb 13, 2026 | clinicaltrials |
| NCT03123029 | Expanded Access to Venetoclax | available | — | — | AbbVieINDUSTRY | 0 | Jan 30, 2026 | clinicaltrials |
| NCT05619367 | A Compassionate Use (CU) Program of Odronextamab | available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Dec 23, 2025 | clinicaltrials |
| NCT04771078 | Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release | available | — | — | CelgeneINDUSTRY | 0 | Dec 12, 2025 | clinicaltrials |
| NCT04400591 | Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol | available | — | — | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 0 | Dec 11, 2025 | clinicaltrials |
| NCT01881334 | Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants | available | — | — | Joanne Kurtzberg, MDOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04745637 | Managed Access Programs for INC424, Ruxolitinib | available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 18, 2025 | clinicaltrials |
| NCT05974410 | Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | available | — | — | AVM Biotechnology IncINDUSTRY | 0 | Oct 2, 2025 | clinicaltrials |
| NCT04008524 | A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies | available | — | — | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03763370 | Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma | available | — | — | GlaxoSmithKlineINDUSTRY | 0 | Oct 15, 2024 | clinicaltrials |
| NCT01250808 | Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy | available | — | — | Peking UniversityOTHER | 1 | Dec 1, 2010 | clinicaltrials |
| NCT00854841 | The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder | available | — | — | Pusan National University HospitalOTHER | 0 | Mar 3, 2009 | clinicaltrials |
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials